BioPharma Dive 14. Jan. 2026 Caldera starts up with $112.5M and a dual-targeting immune drug from China
BioPharma Dive 12. Jan. 2026 JPM26: US biotech’s ‘Sputnik moment,’ Pfizer’s obesity ambitions and Bristol Myers’ big year
BioPharma Dive 12. Jan. 2026 AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations
BioPharma Dive 12. Jan. 2026 Best practices for COA selection: Building a stronger foundation for clinical trials
BioPharma Dive 9. Jan. 2026 Aurora sets out to capitalize on FDA’s new framework for bespoke drug therapies
BioPharma Dive 8. Jan. 2026 Parabilis, chasing ‘undruggable’ targets, nabs $305M amid VC funding blitz